Physician profile
Daniel King
NPI 1760063812
$4,019.00
in general payments reported to CMS, 2019-2025
38 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.12 · 2023: $950 · 2024: $1,052 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $495.20 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $353.57 | 2024-2025 | |
| Lilly USA, LLC | $330.57 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $299.17 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.47 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $240.50 | 2024-2025 | Korlym |
| Dexcom, INC. | $226.01 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $190.33 | 2024-2025 | Minimed 780g |
| Glaxosmithkline, LLC. | $159.42 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $122.28 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $108.20 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $105.31 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $105.17 | 2023-2025 | |
| Cequr Corporation | $100.22 | 2024-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $89.54 | 2025 | Rezdiffra |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $86.15 | 2023 | |
| Amgen INC. | $80.97 | 2023-2025 | Repatha, Otezla, Tepezza |
| Amphastar Pharmaceuticals, INC. | $58.04 | 2024-2025 | Baqsimi |
| Xeris Pharmaceuticals, INC. | $52.68 | 2024-2025 | Gvoke Hypopen |
| Antares Pharma, INC. | $52.50 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals Lp | $43.51 | 2023 | Farxiga, Breztri |
| Ascendis Pharma Endocrinology INC | $41.69 | 2025 | Yorvipath |
| Gilead Sciences, INC. | $41.66 | 2023 | |
| Inspire Medical Systems, INC. | $39.63 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $35.72 | 2023 | Gemtesa |
| Indivior INC. | $29.89 | 2023 | Sublocade |
| Lucid Diagnostics INC. | $28.74 | 2023 | |
| Averitas Pharma INC. | $24.16 | 2025 | Qutenza |
| Halozyme INC | $23.37 | 2023 | |
| Sequel Med Tech, LLC | $19.75 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $19.14 | 2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.86 | 2023 | Xifaxan, Trulance |
| Pfizer INC. | $18.12 | 2023 | |
| Exact Sciences Corporation | $17.22 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $17.02 | 2023 | Wavewriter Alpha Prime 16 |
| Shield Therapeutics INC | $16.36 | 2025 | |
| Axsome Therapeutics, INC. | $16.12 | 2022 | |
| Rgh Enterprises LLC | $15.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.